Interview with Wu Xiaobing, General Manager, Pfizer China
It seems like there’s a lot to be happy about here: Pfizer is ranked number 1 multinational R&D-based biopharmaceutical company in China, where you also have two world-class R&D centers…
Good health is vital to all of us, and finding sustainable solutions to the most pressing health care challenges of our world cannot wait. That’s why we at Pfizer are committed to applying science and our global resources to improve health and well-being at every stage of life. We strive to provide access to safe, effective and affordable medicines and related health care services to the people who need them.
To ensure we can continue to deliver on our commitments to the patients, customers and shareholders who rely on us, we are focused on improving the way we do business; on operating with transparency in everything we do; and on listening to the views of all of the people involved in health care decisions. Through working in partnership with everyone from patients to health care providers and managed care organizations to world governments and non-governmental organizations, our goal is to ensure that people everywhere have access to innovative treatments and quality health care.
Good health is vital to all of us, and finding sustainable solutions to the most pressing health care challenges of our world cannot wait. That’s why we at Pfizer are committed to applying science and our global resources to improve health and well-being at every stage of life. We strive to provide access to safe, effective and affordable medicines and related health care services to the people who need them.
To ensure we can continue to deliver on our commitments to the patients, customers and shareholders who rely on us, we are focused on improving the way we do business; on operating with transparency in everything we do; and on listening to the views of all of the people involved in health care decisions. Through working in partnership with everyone from patients to health care providers and managed care organizations to world governments and non-governmental organizations, our goal is to ensure that people everywhere have access to innovative treatments and quality health care.
Contact:
Address: German Center, Tower 1, 5F, 88 Keyuan Rd, Pudong Zhangjiang Hi-Tech Park, Shanghai, P.R.China 201203
Tel: (021) 28935888
It seems like there’s a lot to be happy about here: Pfizer is ranked number 1 multinational R&D-based biopharmaceutical company in China, where you also have two world-class R&D centers…
Dr James Xue, founder, chairman and CEO of CANbridge Pharmaceuticals shares the career journey that led him to China’s first rare disease-focused company and the role CANbridge is playing in…
Drawing on a wealth of Big Pharma experience, Jenny Zheng now leads China operations for Illumina, a global leader in genomics, specialising in DNA sequencing technology that drives innovation in…
Despite an adverse funding panorama and looming geopolitical tensions, Chinese biotech is still thriving. Companies originating in China are advancing promising pipelines, going public, looking beyond China’s borders with a…
CanSinoBIO was established to create high-quality, affordable vaccines for developing countries, addressing global health disparities. Having already developed an inhalable COVID-19 vaccine, the Chinese firm is now working on new…
Writing in the July 2024 edition of DIA’s Global Forum magazine Mingcan DU and Fengyun (Vicky) HAN of Johnson & Johnson Global Regulatory Policy and Intelligence look back at the…
We last spoke with Xueming Qian, CEO and co-founder of the biotech Transcenta in 2019. Since then, the company has seen some important milestones: listing on the Hong Kong Stock…
General manager Guillaume Delmotte explores Ipsen’s strategic initiatives in China, highlighting the importance of innovation, addressing healthcare challenges, and fostering a sustainable, people-centric organization. Delmotte emphasizes the rapid pace of…
After a Big Pharma career in the US, Dr Yao-Chang Xu returned to China and in 2016 founded Abbisko, a biotech that began with a focus on small molecule oncology…
A roundup of some of the biggest pharma industry news from China, including Fosun’s bid for Henlius Biotech; the revision of the US’s Biosecure Act to provide more time for…
Writing exclusively for PharmaBoardroom, Song Ruilin of the China Pharmaceutical Innovation and Research Development Association (PhIRDA) outlines some of the key improvements and optimisations in the regulatory landscape for pharmaceutical…
Former director general of the Chinese Center for Disease Control and Prevention (CDC) and current chairman of the Chinese Foundation for Hepatitis Prevention and Control, Professor Yu Wang, weighs in…
After a glittering career in corporate America, in 2011 Jasmine Cui returned to China and in 2015 launched her own biotech, Innocare. The firm, which focuses on oncology and autoimmune…
See our Cookie Privacy Policy Here
